James Reddoch compensation by year
Royalty Pharma Summary Compensation Table · all 2 fiscal years held| Component | FY2019 | FY2020 |
|---|---|---|
| Salary | $682,500 | $895,000 |
| Bonus | $1,400,000 | $2,500,000 |
| Stock awards | $0 | $0 |
| Option awards | $0 | $0 |
| Non-equity incentive | $0 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $0 | $0 |
| Total | $2,082,500 | $3,395,000 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Royalty Pharma plc DEF 14A filed April 29, 2021, accession 0001140361-21-014879, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Royalty Pharma plc filed document, accession 0001140361-21-014879. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2021.
Royalty Pharma’s named executive officers, FY2020
as the company reported each| Named executive officer | Role | FY2020 total |
|---|---|---|
| Pablo Legorreta | Chief Executive Officer | $55,674,558 |
| Christopher Hite | Executive Vice President & Vice Chairman | $3,644,711 |
| Terrance Coyne | Executive Vice President & Chief Financial Officer | $3,395,000 |
| George Lloyd | Executive Vice President, Investments & General Counsel | $3,395,000 |
| James Reddoch · this page | Executive Vice President, Research and Investments & Chief Scientific Officer | $3,395,000 |
The full Royalty Pharma compensation record
free company briefThis page is one person within Royalty Pharma's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Royalty Pharma proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Royalty Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.